論文

査読有り
2015年12月

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

JOURNAL OF CLINICAL ONCOLOGY
ダウンロード
回数 : 17
  • Junzo Hamanishi
  • ,
  • Masaki Mandai
  • ,
  • Takafumi Ikeda
  • ,
  • Manabu Minami
  • ,
  • Atsushi Kawaguchi
  • ,
  • Toshinori Murayama
  • ,
  • Masashi Kanai
  • ,
  • Yukiko Mori
  • ,
  • Shigemi Matsumoto
  • ,
  • Shunsuke Chikuma
  • ,
  • Noriomi Matsumura
  • ,
  • Kaoru Abiko
  • ,
  • Tsukasa Baba
  • ,
  • Ken Yamaguchi
  • ,
  • Akihiko Ueda
  • ,
  • Yuko Hosoe
  • ,
  • Satoshi Morita
  • ,
  • Masayuki Yokode
  • ,
  • Akira Shimizu
  • ,
  • Tasuku Honjo
  • ,
  • Ikuo Konishi

33
34
開始ページ
4015
終了ページ
+
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1200/JCO.2015.62.3397
出版者・発行元
AMER SOC CLINICAL ONCOLOGY

Purpose
Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti-PD-1 antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of nivolumab in patients with platinum-resistant ovarian cancer.
Patients and Methods
Twenty patients with platinum-resistant ovarian cancer were treated with an intravenous infusion of nivolumab every 2 weeks at a dose of 1 or 3 mg/kg (constituting two 10-patient cohorts) from October 21, 2011. This phase II trial defined the primary end point as the best overall response. Patients received up to six cycles (four doses per cycle) of nivolumab treatment or received doses until disease progression occurred. Twenty nivolumab-treated patients were evaluated at the end of the trial on December 7, 2014.
Results
Grade 3 or 4 treatment-related adverse events occurred in eight (40%) of 20 patients. Two patients had severe adverse events. In the 20 patients in whom responses could be evaluated, the best overall response was 15%, which included two patients who had a durable complete response (in the 3-mg/kg cohort). The disease control rate in all 20 patients was 45%. The median progression-free survival time was 3.5 months (95% CI, 1.7 to 3.9 months), and the median overall survival time was 20.0 months (95% CI, 7.0 months to not reached) at study termination.
Conclusion
This study, to our knowledge, is the first to explore the effects of nivolumab against ovarian cancer. The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations. (C) 2015 by American Society of Clinical Oncology

Web of Science ® 被引用回数 : 536

リンク情報
DOI
https://doi.org/10.1200/JCO.2015.62.3397
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000366021000009&DestApp=WOS_CPL
ID情報
  • DOI : 10.1200/JCO.2015.62.3397
  • ISSN : 0732-183X
  • eISSN : 1527-7755
  • Web of Science ID : WOS:000366021000009

エクスポート
BibTeX RIS